The Promise of CAR T-Cell Therapy for the Treatment of Cancer Stem Cells: A Short Review

被引：7
|
作者：
Poondla, Naresh [1 ]
Sheykhhasan, Mohsen [2 ,3 ]
Akbari, Mohammad [4 ]
Samadi, Pouria [2 ]
Kalhor, Naser [3 ]
Manoochehri, Hamed [2 ]
机构：
[1] Univ Richmond, Med Ctr, 355 Bard Ave, Staten Isl, NY 10310 USA
[2] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Iran
[3] Acad Ctr Educ Culture & Res ACECR, Dept Mesenchymal Stem Cells, Qom Branch, Tehran, Iran
[4] Islamic Azad Univ, Tonekabon Branch, Dept Med Sch, Fac Med Sci, Mazandaran, Iran
来源：
CURRENT STEM CELL RESEARCH & THERAPY | 2022年 / 17卷 / 05期
关键词：
CAR T-cell; cancer stem cells; malignancy; immunotherapy; antigens; cell surface markers; IMMUNOTHERAPY; CHALLENGES; MARKER; TUMORS;
D O I：
10.2174/1574888X17666220217101817
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Chimeric antigen receptor (CAR) T-cell therapy is a type of sophisticated tailored immunotherapy used to treat a variety of tumors. Immunotherapy works by utilizing the body's own immune system to discover and destroy malignant cells. In CAR-T therapy, a patient's own immune cells are genetically engineered to recognize and attack cancer. Treatments employing CAR T-cells are currently showing promising therapeutic results in patients with hematologic malignancies, and their safety and feasibility in solid tumors have been verified. In this review, we will discuss in detail the likelihood that CAR T-cells inhibit cancer stem cells (CSCs) by selectively targeting their cell surface markers will ultimately improve the therapeutic response for patients with various forms of cancer. This review addresses the major components of cancer stem cell (CSC)-targeted CAR T-cells against malignancies, from bench to bedside.
引用
收藏
页码：400 / 406
页数：7
相关论文
共 50 条
  • [1] CAR T-Cell Therapy: Challenges and Promise
    Till, Brian
    ONCOLOGY-NEW YORK, 2019, 33 (02): : 74 - 74
  • [2] CAR T-Cell Therapy Individualizes Cancer Treatment
    Murphy, Hailey
    CHEMICAL ENGINEERING PROGRESS, 2018, 114 (12) : 57 - 57
  • [3] T-Cell Cancer after CAR T-Cell Therapy
    Mitchell, Emily
    Vassiliou, George S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (22): : 2120 - 2121
  • [4] Biotech Innovations CAR T-Cell Therapy Shows Early Promise for Gastrointestinal Cancer
    Larkin, Howard D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (22): : 2182 - 2182
  • [5] CAR T-cell therapy for gastric cancer: Potential and perspective (Review)
    Long, Bo
    Qin, Long
    Zhang, Boya
    Li, Qiong
    Wang, Long
    Jiang, Xiangyan
    Ye, Huili
    Zhang, Genyuan
    Yu, Zeyuan
    Jiao, Zuoyi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (04) : 889 - 899
  • [6] CAR-modified T-cell therapy for cancer: an updated review
    Haji-Fatahaliha, Mostafa
    Hosseini, Maryam
    Akbarian, Asiye
    Sadreddini, Sanam
    Jadidi-Niaragh, Farhad
    Yousefi, Mehdi
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2016, 44 (06) : 1339 - 1349
  • [7] CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
    Brudno, Jennifer N.
    Maus, Marcela V.
    Hinrichs, Christian S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (22): : 1924 - 1935
  • [8] CAR T-Cell Therapy for Ovarian Cancer
    Yeku, Oladapo
    ONCOLOGIST, 2018, 23 : S3 - S3
  • [9] CAR T-cell therapy for pancreatic cancer
    DeSelm, Carl J.
    Tano, Zachary E.
    Varghese, Anna M.
    Adusumilli, Prasad S.
    JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (01) : 63 - 74
  • [10] The promise of CAR T-cell therapy in aggressive B-cell lymphoma
    Nair, Ranjit
    Neelapu, Sattva S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (03) : 293 - 298
12345